Scienta Lab (Prism)

Nine out of ten drugs fail in clinical development, especially in immunology & inflammation. Scienta helps biopharma derisk I&I pipelines end-to-end from indication and patient selection to trial design and super-responder identification. EVA is the first AI foundation model for I&I. It delivers value across three stages: 

• target prioritization
• translation of preclinical data to human outcomes, and
• patient stratification

Founded in 2021 and backed by $7.5M including the EIC Accelerator, Scienta has published 20 peer-reviewed papers and collaborates with biopharma worldwide.